stockrow
Friday 6 November 2026
Export PRPH’s income statement to Excel — free account
ProPhase Labs, Inc.
PRPH Healthcare Diagnostics & Research
ProPhase Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 35.8% from fiscal 2024.
- Revenue
- −18.9%
- EPS
- +80.0%
- Free cash flow
- +56.7%
- Total debt
- +19.4%
Quarter to June 2026, against a year earlier
0.01
0.00
0.00%
Follow PRPH
Alert me
ProPhase Labs, Inc. (PRPH) P/E ratio
ProPhase Labs, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 146× (May 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 8.0× | (55.51%) |
| FY2021 | 17.9× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.8× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 146×
Ten-year median
0.0×
Current reading's percentile
73
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DMTKQ DermTech, Inc. compare | n/m |
| ISPC iSpecimen Inc. compare | n/m |
| XWEL XWELL, Inc. compare | n/m |
| NDRA ENDRA Life Sciences Inc. compare | n/m |
| BIAF bioAffinity Technologies, Inc. compare | n/m |
| TTOO T2 Biosystems, Inc. compare | n/m |
| PRPH ProPhase Labs, Inc. | n/m |
| AWHL Aspira Women's Health Inc. compare | n/m |
| ADVB Advanced Biomed Inc. compare | 0.3× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)